Denosumab regimens in the treatment of giant cell tumor of bone: A systematic review with meta-analysis

Figure 1 PRISMA 2020 flow diagram for new systematic reviews which included searches of databases, registers, and other sources.

Figure 2 Random-effects model. A: Calculation of clinical benefit rates with denosumab therapy; B: Sensitivity analysis by methodological design of studies that evaluated clinical benefit; C: Subgroup analysis (number of doses) of studies that evaluated clinical benefit; D: Calculation of local recurrence rates with denosumab therapy; E: Sensitivity analysis by methodological design of studies that evaluated local recurrence; F: Subgroup analysis (number of doses) of studies that evaluated local recurrence; G: Calculation of imaging response rates with denosumab therapy; H: Sensitivity analysis by methodological design of studies that evaluated imaging response; I: Subgroup analysis(number of doses) of studies that evaluated imaging response.